An observational study in Rectal Cancer, Synchronous Liver Metastases and Antineoplastic Combined Chemotherapy Protocols, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 160 studies in Rectal Neoplasms with a site in France — 28 open to participants now, 40 under way, 6 of them phase 3. Rectal Neoplasms · France.
Among the 160 studies in Rectal Neoplasms with a site in France, this one is the 6th largest by planned enrollment of the 27 observational ones that give a count, is one of 7 that started in 2026, is one of 27 observational ones, reaches primary completion later than 36 of the 39 other live ones, and was the 156th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →28 of the 160 studies in Rectal Neoplasms with a site in France are open now. Recruiting first, the newest first:
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 18+
Medical University of Gdansk · Sites in France, Poland
Ages 18+
University Hospital, Rouen · Sites in France
Ages 18–60
Institut du Cancer de Montpellier - Val d'Aurelle · Sites in France
Ages 18+
GlaxoSmithKline · Sites in France, United States, Canada and 6 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
160 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 51 · Phase 3 40 · Phase 4 2
First in 1993; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 550 is above the median of 161 across 499 observational studies indexed under Rectal Neoplasms.
Median enrollment 109 across the 120 interventional studies, 100 across the 27 observational. Of the 96 that completed or were terminated, 12 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 160 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 9 studies filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
8 of the studies in Rectal Neoplasms with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03875781Phase 3Assistance Publique - Hôpitaux de ParisNon Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer | 2026-12-05 |
| NCT06923150Qufora A/SA Randomised Clinical Investigation to Assess Efficacy of Low Volume Transanal Irrigation by Qufora® IrriSedo MiniGo Versus Conservative Treatment for Low Anterior Resection Syndrome Patients | 2026-12 |
| NCT07000474University Hospital, BrestMultiparametric Characterization of Colorectal Cancers (METRAD) | 2026-12-31 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
| NCT05933122University Hospital, LimogesStudy of the Prevalence of Sexual Dysfunction in Women After Rectal Cancer Surgery and Analysis of the Impact of a Sexologist Intervention | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 160 studies in Rectal Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
SYNCHRONOX is a multicenter cohort (retrospective then prospective) intending to include 550 patients with mid or low rectal adenocarcinoma (pMMR, T3-T4 and/or N+) and resectable synchronous liver metastases, treated upfront with at least two cycles of induction FOLFIRINOX chemotherapy. The primary objective is to determine, at 18 months, the R0 resection rate of both tumor sites (rectum and liver), while secondary objectives focus on 3 year overall and progression free survival, radiological and pathological responses, postoperative morbidity and mortality, and comparison of the different surgical strategies after FOLFIRINOX.
SYNCHRONOX is a multicenter, observational retrospective cohort followed by a prospective validation cohort designed to evaluate therapeutic pathways and oncologic outcomes in adults with mid- or low-rectal adenocarcinoma and resectable synchronous liver metastases who received induction FOLFIRINOX chemotherapy. The study aims to describe and compare real-world management strategies after induction FOLFIRINOX (simultaneous rectum and liver surgery, "classic" rectum-first, "reverse" liver-first, and adaptive sequencing) and to identify factors associated with achieving complete curative-intent treatment of both tumor sites.
Eligible patients are ≥18 years old with pMMR mid/low rectal adenocarcinoma staged cT3-T4 and/or N+, with synchronous liver metastases diagnosed within 3 months before or after the rectal cancer diagnosis, without extrahepatic metastases, and treated with at least two cycles of induction FOLFIRINOX. Liver disease is considered resectable when lesions are unilobar (no limit in number) or bilobar with up to 10 lesions, corresponding to class I (clearly resectable with a conventional hepatectomy of ≤4 segments leaving >40% remnant liver) or class II (potentially resectable, requiring complex/extended liver surgery and possibly two-stage strategies). Because this is a non-interventional study, all diagnostic work-up, chemotherapy, radiotherapy, surgical decisions, and follow-up are performed as part of routine care and remain at the discretion of local multidisciplinary tumor boards. The research does not mandate any additional clinical, laboratory, radiologic examinations, surgical procedures, or questionnaires.
The primary endpoint is the rate of curative-intent complete treatment (R0) of both tumor sites at 18 months after the start of induction FOLFIRINOX. For rectal cancer, R0 resection is defined as a distal margin ≥1 cm and a circumferential resection margin >1 mm. Organ preservation without surgery is also considered curative-intent when achieved after a clinical complete response and not followed by tumor regrowth within the first year. For liver metastases, curative-intent treatment requires R0 resection of all visible lesions (margin >1 mm) and/or local destruction by radiofrequency ablation.
Secondary objectives include overall survival and progression-free survival at 3 years from the start of FOLFIRINOX, R0 resection rates for the rectal primary and liver metastases separately, radiologic response assessment at both sites (ymrTRG for rectal MRI response and RECIST for liver lesions), pathologic tumor regression grading (Rödel score for rectal cancer and Blazer classification for liver metastases), clinical complete response rate of the rectal tumor, and 30-day postoperative morbidity and mortality after rectal and liver surgery (Dindo-Clavien classification). Data are collected in an electronic case report form (eCRF) from standard medical records for both retrospective and prospective cohorts, with planned comparative analyses between strategies using matching variables and propensity-score methods to limit indication bias. The retrospective cohort includes patients diagnosed between June 1, 2020 and June 1, 2025, and the prospective validation cohort includes patients diagnosed between June 1, 2025 and June 1, 2028, with an overall follow-up duration of 60 months.
Patients with mid/lower rectal cancer with resectable synchronous liver metastases, treated with FOLFIRINOX induction chemotherapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Follow-up as part of the usual care of patients with mid/lower rectal cancer with resectable synchronous liver metastases, treated with FOLFIRINOX induction chemotherapy.
Curative resection rate of both tumor sites after induction chemotherapy with FOLFIRINOX
For rectal cancer, resection is considered curative in cases of R0 resection (distal margin ≥ 1 cm and circumferential resection margin \> 1 mm). Non-surgical organ preservation is also considered curative treatment in cases of complete clinical response not followed by tumor regrowth during the first year. For liver metastases, resection is considered curative if all visible lesions have been resected R0 (resection margin \> 1 mm) or destroyed by radiofrequency.
Time frame: 18 months from the start of chemotherapy with FOLFIRINOX
Overall 3-year survival rate
The length of time from the start of FOLFIRINOX chemotherapy until death.
Time frame: 3 years from the start of chemotherapy with FOLFIRINOX
Three-year progression-free survival rate
Survival is calculated from the start of treatment with FOLFIRINOX chemotherapy. Any progression during preoperative treatment preventing complete resection for curative purposes, the discovery of a contraindication to surgery during the operation, and the occurrence of recurrence after surgery will be considered an event.
Time frame: 3 years from the start of chemotherapy with FOLFIRINOX
Complete resection rate (R0) of rectal tumors
Resection is considered complete (R0) if the distal margin is ≥ 1 cm and the circumferential resection margin is \> 1 mm.
Time frame: 30 days after rectal resection
Complete resection rate (R0) of liver lesions
Resection is considered complete (R0) if the resection margin is \> 1 mm.
Time frame: 30 days after liver resection
Radiological response grade of rectal tumor to preoperative treatment
The radiological response will be assessed using the Magnetic Resonance Tumor Regression Grade (ymrTRG), a five-grade scale ranging from 1 (complete response) to 5 (no response).
Time frame: 1 month after the end of neoadjuvant therapy
Radiological response grade of liver lesions to preoperative treatment
The radiological response will be assessed using the RECIST score (partial response (response \> 30%), complete response (response 100%), progression (increase in lesion size \> 20%), stability (progression \< 20% and response \< 30%)).
Time frame: 1 month after the end of FOLFIRINOX
Histological response grade of rectal tumor to preoperative treatment
The histological response grade will be assessed according to the Rödel score, a five-grade scale ranging from 0 (zero regression) to 4 (complete response).
Time frame: 30 days after rectal resection
Histological response grade of liver lesions to preoperative treatment
The histological response grade is estimated according to Blazer. The Blazer score identifies three subgroups: 1. Complete response: absence of residual cancer cells; 2. Major response: presence of 1% to 49% of residual cancer cells; 3. Minor response: presence of ≥ 50% of residual cancer cells. In patients with multiple tumor nodules, the average of the values for the different nodules will be used to define the pathological response.
Time frame: 30 days after liver resection
Complete clinical response rate of rectal tumors
Complete clinical response is defined by a complete radiological response on MRI (ymrTRG1) and no palpable lesion on digital rectal examination, and on endoscopy, no visible tumor or only a residual whitish scar without ulceration.
Time frame: 1 month after neoadjuvant treatment
Postoperative complication rate following rectal surgery
Postoperative complication rates according to Dindo-Clavien (1=minor medical treatment; 2=antibiotic therapy, transfusion, parenteral nutrition; 3=surgical treatment, interventional radiology or endoscopy; 4=hospitalization in intensive care unit; 5=death).
Time frame: 30 days post operative
Postoperative complication rate following liver surgery
Postoperative complication rates according to Dindo-Clavien (1=minor medical treatment; 2=antibiotic therapy, transfusion, parenteral nutrition; 3=surgical treatment, interventional radiology or endoscopy; 4=hospitalization in intensive care unit; 5=death).
Time frame: 30 days post operative
Postoperative mortality rate following rectal surgery
Death within 30 days following rectal surgery.
Time frame: 30 days post operative
Postoperative mortality rate following liver surgery
Death within 30 days following liver surgery.
Time frame: 30 days post operative
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Nov 2030, 54 months after the start.
Of 214 non-industry observational studies under Rectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 118. This study's planned 54 months is above that.
Counting every sponsor, half of 229 studies reached it within 45 months; a quarter within 24 and three quarters within 116.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →